NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2, sidero- calin) is a novel biomarker for diagnosing acute kidney injury (AKI). Under normal conditions NGAL levels are low in urine and plasma Still, they rise sharply from basal levels in response to kidney injury to reach diagnostic levels within a very short time - as much as 24 hours or more before any significant rise in serum creatinine.
C-peptide Rapid Quantitative Test (Chemiluminescence Immunoassay) is used for in vitro quantitative detection of the C-peptide concentration in human serum and plasma that contains heparin /EDTA and other anticoagulants samples, mainly used for auxiliary diagnosis of diabetes diseases.
IPv6 network supported 
